Fig. 1From: Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinomaKaplan–Meier curves of progression-free survival (PFS) and overall survival (OS) of patients with metastatic renal cell carcinoma treated with sorafenib and sunitinib. No significant differences in both PFS and OS were observed between the two groupsBack to article page